Back to list

Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A1chieve study

Nabil K. El Naggar, Pradana Soewondo, Mohammad E. Khamseh, Jian-Wen Chen and Jihad Haddad

Diabetes Research and Clinical Practice, 3, 98, pages 408 - 413

Published online Dec-2012


Article view:

Acknowledgements

The authors would like to thank all of the investigators involved in the A1chieve® study. The authors would like to thank Chundo Shen of Novo Nordisk for providing Statistical Analyses. The authors would also like to thank Michael Lappin of Watermeadow Medical for writing assistance, funded by Novo Nordisk. This study was sponsored by Novo Nordisk A/S, Denmark.


Back to list